DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Christian Hartmann - 1 Jean - 1 Luc Lagardere - 1 Alain Carpentier - 1 Carpentier - 1 Stephane Piat - 1 Emmanuel Macron - 1 Thomas Toepfer - 1
Top related locs:
Velizy Paris French Carmat United States Lagardere Taiwan
Top related orgs:
REUTERS - 1 Rights - 1 Airbus - 1 PARIS - 1 Lagardere's Matra Defense - 1 Carmat - 1 Rx Securities - 1 FDA - 1

Search resuls for: "Samir Devani"


3 mentions found


☆ Artificial heart maker Carmat's future seen in hands of core backers
  + stars: | 2023-09-29 | by ( Michal Aleksandrowicz Tim Hepher Laura Lenkiewicz | Michal Aleksandrowicz | Tim Hepher | ) www.reuters.com   time to read: +4 min
An artificial heart by French manufacturer Carmat is seen during an interview with Reuters in Velizy, near Paris, January 11, 2021. Sources said Carmat, which had 24 million euros cash at mid-year, was looking to raise a total of around 100 million. Airbus said this week it had invested 50 million euros in Carmat but did not address whether it would spend more. It most recently invested 10 million euros in March 2022. Matra Defense paid a dividend of 207 million euros to Airbus in 2022, filings show.
Persons: Christian Hartmann, Jean, Luc Lagardere, Alain Carpentier, Carpentier, Stephane Piat, Emmanuel Macron, Thomas Toepfer, Piat, Samir Devani, Carmat, Tim Hepher, Michal Aleksandrowicz, Laura Lenkiewicz, Stephanie Hamel, Josephine Mason, Elaine Hardcastle Organizations: Reuters, REUTERS, Rights, Airbus, PARIS, Lagardere's Matra Defense, Carmat, Rx Securities, FDA, Zurich University, Matra Defense, Thomson Locations: Velizy, Paris, French, Carmat, United States, Lagardere, Taiwan
☆ Pfizer, Valneva to stop testing Lyme disease vaccine in some U.S. patients
  + stars: | 2023-02-17 | by ( Bhanvi Satija | ) www.reuters.com   time to read: +2 min
[1/2] Pfizer company logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna GeronFeb 17 (Reuters) - Drugmaker Pfizer Inc (PFE.N) and France's Valneva (VLS.PA) will stop testing a Lyme disease vaccine in roughly half of U.S. patients in a late-stage study, the companies said, citing a breach of clinical trial guidelines by a third-party contractor. Pfizer still expects to submit marketing applications for the experimental vaccine in the United States and Europe in 2025. The trial was expected to include around 6,000 participants aged 5 and older across Europe and United States, where Lyme disease is highly endemic. Paris-listed shares of Valneva fell nearly 10% to 5.72 euros following the news and U.S.-listed shares of Pfizer were down marginally in premarket trading.
☆ Valneva in talks with potential partner on second-gen COVID-19 vaccines
  + stars: | 2022-09-26 | by ( ) www.reuters.com   time to read: +2 min
Register now for FREE unlimited access to Reuters.com RegisterValneva logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration/File PhotoPARIS, Sept 26 (Reuters) - French drugmaker Valneva (VLS.PA) said on Monday it is in talks with a potential partner on producing an updated version of its COVID-19 vaccine that targets new variants of the disease, sending its shares up. The French company has struggled to bring its COVID-19 vaccine to market to compete with rival products from drugmakers such as AstraZeneca, Moderna and BioNTech/Pfizer. "The company is in active discussions with a prospective partner for potentially funding the development of a second-generation COVID-19 vaccine," Valneva said. Register now for FREE unlimited access to Reuters.com RegisterReporting by Tassilo Hummel and Darmarah Mackos; Editing by Sudip Kar-GuptaOur Standards: The Thomson Reuters Trust Principles.
0 next >>
Total: 3